


PHARMACEUTICAL 2023

Cell Source Inc. Rank 430 of 446





PHARMACEUTICAL 2023

Cell Source Inc. Rank 430 of 446

The relative strengths and weaknesses of Cell Source Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cell Source Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 344% points. The greatest weakness of Cell Source Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 234% points.

The company's Economic Capital Ratio, given in the ranking table, is -400%, being 443% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	0
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	680
Liabilities, Non-Current	0
Other Assets	410
Other Compr. Net Income	0
Other Expenses	58
Other Liabilities	12,363
Other Net Income	-992
Other Revenues	0
Property and Equipment	0
Research and Development	1,938
Selling, General and Administrative Expense	2,179

Output Variable	Value in 1000 USD
Assets	410
Liabilities	13,044
Expenses	4,175
Revenues	0
Stockholders Equity	-12,634
Net Income	-5,168
Comprehensive Net Income	-5,168
Economic Capital Ratio	-400%

